Your Cart
Product Title
2 x $5566
Total:$11132.00
BTL Biotechno Labs Pvt. Ltd. offers a comprehensive range of DNA technologies for custom antibody services. By integrating antibody gene sequencing, de novo antibody design, antibody humanization, antibody gene synthesis, recombinant antibody expression, monoclonal antibody preparation, and polyclonal antibody preparation, our technical platforms cover all stages of antibody discovery. Our motive is to provide support in the development of biobased medicines by offering high-quality research products and cost-effective solutions to the biotechnology, pharmaceutical, and academic communities.
Clonal B cells and hybridoma cell lines are two examples of monoclonal antibody sequencing. After screening, both of these types of cells can produce a single antibody directed against a particular antigen. For accurate and effective hybridoma/clonal B cell sequencing services across a range of species, either Sanger or 5'RACE sequencing technologies are used. We offer a quick and simple method to sequence your hybridoma antibodies, assisting you in finding the most promising therapeutic leads for next-generation drug development.
The term "immune repertoire" refers to the total number of functionally diverse B cells and T cells that are present in an individual’s circulatory system at any given time. Targeting T/B cells, immune repertoire sequencing (Immuno-Seq) makes use of the 5' Rapid Amplification of cDNA Ends (RACE) Technology. Complementarity-determining regions (CDRs) of T cell receptors (TCRs) or B cell receptors (BCRs) are amplified by the 5' RACE technique. When used in conjunction with high-throughput sequencing technologies, Immuno-Seq offers a thorough analysis of the immune system diversity.
BTL Biotechno Labs Pvt. Ltd. provides a complete antibody repertoire sequencing system comprising immune repertoire sequencing, antibody CDR region sequencing, etc. The Immuno-Seq System is designed to help scientists observe and study T and B cells with unprecedented specificity. The immuno-Seq technique can be used for disease surveillance, antibody generation, vaccine research, health evaluation, and other related applications due to its specificity.
High-quality sequencing of monoclonal antibodies from diverse species, including mice, rats, Armenian hamsters, camels, rabbits, equines, bovines, canines, birds, etc., can be performed via this platform. The Syno® Ab Platform is an effective computer-aided technology that can perform de novo sequencing analysis using antibodies from several antibody libraries, making the platform very applicable.
Any species or isotype's hybridoma sequence can be precisely obtained. A final recombinant antibody product will be delivered to support scientific research in a timely and cost-effective manner with high-throughput antibody manufacturing techniques.
Antibody drugs are among the most promising therapies, have experienced massive growth as new drugs, and have been approved for use in treating numerous diseases. BTL Biotechno Labs Pvt. Ltd. offers a fast, reliable, flexible, and customised one-step solution to antibody discovery. The GenoAb platform includes hybridoma and monoclonal antibody sequencing, immune repertoire sequencing, and phage display. We have a platform for structure-based in silico antibody discovery that can screen early hits for antigens for wet-lab evaluation.
A platform for integrated antibody humanization and affinity maturation has been developed using cutting-edge phage and yeast display technology and sophisticated computer modelling and simulation methodologies. BTL Biotechno Labs Pvt. Ltd. offers in-silico CDR-grafting, computer-aided design and optimisation, high-throughput phage-display custom antibody products screening, and biacore surface resonance analysis as part of antibody humanization services. With this method, humanised antibodies with reduced immunogenicity can be produced that are as good as or better than parental antibodies in terms of specificity, bioactivity, thermostability, and productivity.
The binding affinity is one of the key factors in determining the effectiveness and dosage of an antibody drug. Currently, site mutation, CDR rearrangement, DNA recombinant, etc. are the main techniques used to increase the binding affinity of antibodies. We provide services for the identification of amino acid positions in the antibody domain with an efficient affinity maturation process. In turn, the antibody's binding affinity rises as a result, reaching at least nM levels.
Single-domain antibodies (sdAb), a new type of designed antibody fragments, are recombinant antibodies that are composed of a single monomeric variable antibody domain. sdAbs are more stable, more soluble, and smaller than traditional antibodies. Additionally, sdAb has simpler and more affordable production processes, higher permeability, decreased immunogenicity, and lower production costs.
Drop your email address to get regular updates about discounts and offers